跳转至内容
Merck
所有图片(2)

文件

94496

Supelco

卡马西平

analytical standard

别名:

5H-二苯并[b,f]氮杂-5-甲酰胺

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C15H12N2O
CAS号:
298-46-4
分子量:
236.27
EC號碼:
206-062-7
MDL號碼:
MFCD00005073
分類程式碼代碼:
41116107
PubChem物質ID:
329770347
NACRES:
NA.24

等級

analytical standard

品質等級

100

化驗

≥99.0% (HPLC)

儲存期限

limited shelf life, expiry date on the label

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

雜質

≤0.5% water

mp

191-192 °C (lit.)

應用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI 密鑰

FFGPTBGBLSHEPO-UHFFFAOYSA-N

基因資訊

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

正在寻找类似产品? 访问 产品对比指南

相关类别

應用

有关合适的仪器技术的更多信息，请参阅产品的分析证书。想要获得更多支持，请联系技术服务部。

生化／生理作用

抗惊厥药；GABAA受体苯二氮卓调节位点的配体。钠离子通道抑制剂。

推薦產品

在我们的NMR在线平台ChemisTwin®上可以找到本品对应的数字化标准物质。您可使用ChemisTwin®上的数字等效品鉴定您的样品并进行定量分析（使用数字化外标）。可查看该物质的NMR谱图，只需点击几次鼠标，就能进行在线样品比对。欢迎点击了解更多，开启免费试用之旅。

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

標靶器官

Central nervous system

儲存類別代碼

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number
BCCM1536
BCCH4703
BCCD8003
BCCB9994
BCBX3991

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Sandeep Grover et al.
Pharmacogenetics and genomics, 24(2), 94-112 (2013-12-18)
A considerable heterogeneity exists in the literature on the role of different HLA alleles in carbamazepine (CBZ)-induced cutaneous adverse drug reactions (cADRs) of varying severity among diverse ethnic groups. The aim of the present study was to understand and summarize
Wimonchat Tangamornsuksan et al.
JAMA dermatology, 149(9), 1025-1032 (2013-07-26)
The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门